vatalanib has been researched along with Metastase in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 10 (71.43) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baker, AF; Bolejack, V; Burris, H; Crowley, J; Dayyani, F; Dragovich, T; Hidalgo, M; Laheru, D; Raghunand, N; Ritch, P; Rosen, P; Seng, J; Smith, L; Von Hoff, DD | 1 |
| Alsop, DC; de Bazelaire, C; George, D; Michaelson, MD; Pedrosa, I; Rofsky, NM; Wang, Y | 1 |
| Köhne, CH; Lenz, HJ | 1 |
| Brueggen, J; Lane, HA; Littlewood-Evans, A; McSheehy, PM; O'Reilly, T; Schnell, C; Wood, JM | 1 |
| Bajetta, E; Berg, W; Chen, BL; Germond, C; Hecht, JR; Jalava, T; Köhne, CH; Laurent, D; Lebwohl, D; Lin, E; Meinhardt, G; Moore, M; Valle, J; Van Cutsem, E | 1 |
| Berg, W; Bodoky, G; Chen, BL; Hainsworth, JD; Hecht, JR; Jäger, E; Jalava, T; Kerr, D; Laurent, D; Lebwohl, D; Lloyd-Salvant, K; Major, P; Meinhardt, G; Pendergrass, K; Trarbach, T; Wolff, RA | 1 |
| Ellis, LM | 1 |
| Ball, HA; Buchert, M; Cherryman, GR; Drevs, J; Dugan, M; Fuxuis, S; Hennig, J; Henry, A; Horsfield, MA; Jivan, A; Laurent, D; Lee, L; Marmé, D; Mietlowski, W; Morgan, B; Mross, K; O'Byrne, K; Steward, WP; Thomas, AL; Unger, C | 1 |
| Morse, MA | 1 |
| Los, M; Roodhart, JM; Voest, EE | 1 |
| Bueter, M; Fein, M; Gasser, M; Illert, B; Meyer, D; Reimer, P; Thalheimer, A; Thiede, A; Waaga-Gasser, AM | 1 |
| Bold, G; Buchdunger, E; Cozens, R; Drevs, J; Ferrari, S; Frei, J; Hofmann, F; Martiny-Baron, G; Menrad, A; Mestan, J; Mett, H; O'Reilly, T; Persohn, E; Rösel, J; Schirner, M; Schneider, MR; Schnell, C; Siemeister, G; Stover, D; Theuer, A; Thierauch, KH; Totzke, F; Towbin, H; Wenger, F; Wood, JM; Woods-Cook, K | 1 |
| Baker, CH; Bruns, CJ; Ellis, LM; Fidler, IJ; Killion, JJ; Solorzano, CC; Wood, J | 1 |
| Baker, CH; Fidler, IJ; Solorzano, CC | 1 |
3 review(s) available for vatalanib and Metastase
| Article | Year |
|---|---|
Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Cetuximab; Clinical Trials as Topic; Colorectal Neoplasms; ErbB Receptors; Humans; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2009 |
Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Bevacizumab; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A | 2007 |
[Antibody treatment in colorectal cancer--what the surgeon needs to know].
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Bevacizumab; Camptothecin; Cetuximab; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Colorectal Neoplasms; Drug Therapy, Combination; Epidermal Growth Factor; ErbB Receptors; Fluorouracil; Humans; Irinotecan; Leucovorin; Neoplasm Metastasis; Panitumumab; Phthalazines; Pyridines; Randomized Controlled Trials as Topic; Vascular Endothelial Growth Factor A; Vitamin B Complex | 2008 |
5 trial(s) available for vatalanib and Metastase
| Article | Year |
|---|---|
Phase II trial of vatalanib in patients with advanced or metastatic pancreatic adenocarcinoma after first-line gemcitabine therapy (PCRT O4-001).
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Deoxycytidine; Enzyme-Linked Immunosorbent Assay; Female; Follow-Up Studies; Gemcitabine; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Neoplasm Staging; Pancreatic Neoplasms; Phthalazines; Prognosis; Pyridines; Survival Rate | 2014 |
Magnetic resonance imaging-measured blood flow change after antiangiogenic therapy with PTK787/ZK 222584 correlates with clinical outcome in metastatic renal cell carcinoma.
Topics: Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease Progression; Feasibility Studies; Humans; Kidney Neoplasms; Magnetic Resonance Imaging; Neoplasm Metastasis; Neovascularization, Pathologic; Phthalazines; Pyridines; Regional Blood Flow | 2008 |
Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Pyridines | 2011 |
Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Colorectal Neoplasms; Disease-Free Survival; Female; Fluorouracil; Humans; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Oxaliplatin; Phthalazines; Placebos; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor | 2011 |
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liv
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Biomarkers; Colorectal Neoplasms; Contrast Media; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Phthalazines; Predictive Value of Tests; Pyridines; Treatment Outcome | 2003 |
6 other study(ies) available for vatalanib and Metastase
| Article | Year |
|---|---|
Everolimus and PTK/ZK show synergistic growth inhibition in the orthotopic BL16/BL6 murine melanoma model.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Everolimus; Female; Mechanistic Target of Rapamycin Complex 1; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Models, Biological; Multiprotein Complexes; Neoplasm Metastasis; Phthalazines; Proteins; Pyridines; Receptors, Vascular Endothelial Growth Factor; Sirolimus; TOR Serine-Threonine Kinases | 2011 |
Antiangiogenic therapy: more promise and, yet again, more questions.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Humans; Liver Neoplasms; Neoplasm Metastasis; Phthalazines; Pyridines | 2003 |
Perspectives in colorectal cancer - Sixth Annual Conference. Metastatic colorectal cancer.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Capecitabine; Colorectal Neoplasms; Cyclooxygenase 2 Inhibitors; Deoxycytidine; ErbB Receptors; Fluorouracil; Humans; Neoplasm Metastasis; Phthalazines; Pyridines; Vascular Endothelial Growth Factor A | 2005 |
PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration.
Topics: Angiogenesis Inhibitors; Animals; Bone Marrow Cells; Carcinoma; Cell Division; Disease Models, Animal; Dose-Response Relationship, Drug; Endothelial Growth Factors; Endothelium, Vascular; Hematopoiesis; Humans; Kidney Neoplasms; Leukocytes; Lymphokines; Mice; Mice, Nude; Neoplasm Metastasis; Neoplasm Transplantation; Neovascularization, Pathologic; Phosphorylation; Phthalazines; Platelet-Derived Growth Factor; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Wound Healing | 2000 |
Inhibition of growth and metastasis of human pancreatic cancer growing in nude mice by PTK 787/ZK222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Deoxycytidine; Enzyme Inhibitors; Gemcitabine; Humans; In Situ Nick-End Labeling; Male; Mice; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Proteins; Neoplasm Transplantation; Pancreatic Neoplasms; Phthalazines; Platelet Endothelial Cell Adhesion Molecule-1; Proliferating Cell Nuclear Antigen; Pyridines; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2001 |
Blockade of vascular endothelial growth factor receptor and epidermal growth factor receptor signaling for therapy of metastatic human pancreatic cancer.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Division; Deoxycytidine; Endothelium, Vascular; ErbB Receptors; Gemcitabine; Humans; Immunohistochemistry; Male; Mice; Mice, Nude; Neoplasm Metastasis; Neovascularization, Pathologic; Pancreatic Neoplasms; Phthalazines; Pyridines; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Receptors, Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Xenograft Model Antitumor Assays | 2002 |